Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 641962, 10 pages
http://dx.doi.org/10.1155/2014/641962
Clinical Study

Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease

1Servicio de Nefrología, Instituto de Investigacion Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
2Servicio de Inmunología, Instituto de Investigacion Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
3Servicio de Epidemiología, Instituto de Investigacion Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
4Sección de Inmunología, Universidad San Pablo-CEU, Campus de Monteprincipe, 28668 Madrid, Spain
5Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain

Received 23 January 2014; Revised 10 March 2014; Accepted 10 March 2014; Published 10 April 2014

Academic Editor: Jozélio Freire De Carvalho

Copyright © 2014 Manuel Serrano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Leskinen, T. Lehtimäki, A. Loimaala et al., “Carotid atherosclerosis in chronic renal failure—the central role of increased plaque burden,” Atherosclerosis, vol. 171, no. 2, pp. 295–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Kovacic, D. Ljutic, J. Dodig, M. Radic, and D. Duplancic, “Influence of haemodialysis on early markers of atherosclerosis,” Nephrology, vol. 13, no. 6, pp. 472–479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Epidemiology of cardiovascular disease in chronic renal disease,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. S16–S23, 1998. View at Google Scholar · View at Scopus
  4. M. J. Sarnak, “Cardiovascular complications in chronic kidney disease,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. S11–S17, 2003. View at Google Scholar · View at Scopus
  5. H. Pilmore, H. Dent, S. Chang, S. P. McDonald, and S. J. Chadban, “Reduction in cardiovascular death after kidney transplantation,” Transplantation, vol. 89, no. 7, pp. 851–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Berthoux and C. Mariat, “Cardiovascular death after renal transplantation remains the first cause despite significant quantitative and qualitative changes,” Transplantation, vol. 89, no. 7, p. 806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. A. Triplett, “Antiphospholipid antibodies,” Archives of Pathology and Laboratory Medicine, vol. 126, no. 11, pp. 1424–1429, 2002. View at Google Scholar · View at Scopus
  8. P. G. de Groot and R. T. Urbanus, “The significance of autoantibodies against beta2-glycoprotein I,” Blood, vol. 120, no. 2, pp. 266–274, 2012. View at Google Scholar
  9. S. S. Pierangeli, P. P. Chen, E. Raschi et al., “Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 3, pp. 236–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. K. Moestrup, I. Schousboe, C. Jacobsen, J.-R. Leheste, E. I. Christensen, and T. E. Willnow, “β2-glycoprotein-I (apolipoprotein H) and β2-glycoprotein-I- phospholipid complex harbor a recognition site for the endocytic receptor megalin,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 902–909, 1998. View at Google Scholar · View at Scopus
  11. D. A. Klærke, R. Røjkjær, L. Christensen, and I. Schousboe, “Identification of β2-glycoprotein I as a membrane-associated protein in kidney: Purification by calmodulin affinity chromatography,” Biochimica et Biophysica Acta, vol. 1339, no. 2, pp. 203–216, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Murthy, R. Willis, Z. Romay-Penabad et al., “Value of isolated IgA anti-beta GPI positivity in the diagnosis of the antiphospholipid syndrome,” Arthritis & Rheumatology, vol. 65, no. 12, pp. 3186–3193, 2013. View at Google Scholar
  14. H. L. Staub, M. Franck, A. Ranzolin, G. L. Norman, G. M. Iverson, and C. A. von Mühlen, “IgA antibodies to beta2-glycoprotein I and atherosclerosis,” Autoimmunity Reviews, vol. 6, no. 2, pp. 104–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Andreoli, M. Fredi, C. Nalli et al., “Clinical significance of IgA anticardiolipin and IgA anti-beta2glycoprotein I antibodies,” Current Rheumatology Reports, vol. 15, no. 7, article 343, 2013. View at Google Scholar
  16. J. A. Martinez-Flores, M. Serrano, J. Alfaro et al., “Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology,” Analytical Chemistry, vol. 85, no. 24, pp. 12093–12098, 2013. View at Publisher · View at Google Scholar
  17. I. Uthman and M. Khamashta, “Antiphospholipid syndrome and the kidneys,” Seminars in Arthritis and Rheumatism, vol. 35, no. 6, pp. 360–367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Gronhagen-Riska, A.-M. Teppo, A. Helantera, E. Honkanen, and H. Julkunen, “Raised concentrations of antibodies to cardiolipin in patients receiving dialysis,” British Medical Journal, vol. 300, no. 6741, pp. 1696–1697, 1990. View at Google Scholar · View at Scopus
  19. P. Brunet, M.-F. Aillaud, M. San Marco et al., “Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis,” Kidney International, vol. 48, no. 3, pp. 794–800, 1995. View at Google Scholar · View at Scopus
  20. J. Matsuda, N. Saitoh, K. Gohchi, M. Tsukamoto, K. Nakamura, and T. Kinoshita, “β2-Glycoprotein I -Dependent and -independent anticardiolipin antibody in patients with end-stage renal disease,” Thrombosis Research, vol. 72, no. 2, pp. 109–117, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Garcia-Martin, G. De Arriba, T. Carrascosa et al., “Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease,” Nephrology Dialysis Transplantation, vol. 6, no. 8, pp. 543–547, 1991. View at Google Scholar · View at Scopus
  22. Y. S. Haviv, “Association of anticardiolipin antibodies with vascular injury: possible mechanisms,” Postgraduate Medical Journal, vol. 76, no. 900, pp. 625–628, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. E. E. Gharavi, H. Chaimovich, E. Cucurull et al., “Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides,” Lupus, vol. 8, no. 6, pp. 449–455, 1999. View at Google Scholar · View at Scopus
  24. S. Ozmen, R. Danis, D. Akin, and S. Batun, “Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure,” Clinical Nephrology, vol. 72, no. 3, pp. 193–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Roozbeh, A.-R. Serati, and S.-A. Malekhoseini, “Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients,” Archives of Iranian Medicine, vol. 9, no. 1, pp. 26–32, 2006. View at Google Scholar · View at Scopus
  26. G. J. Pons-Estel and R. Cervera, “Renal involvement in antiphospholipid syndrome,” Current Rheumatology Reports, vol. 16, no. 2, article 397, 2014. View at Google Scholar
  27. A. Serrano, F. García, M. Serrano et al., “IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality,” Kidney International, vol. 81, pp. 1239–1244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Hadhri, M. B. Rejeb, A. Belarbia, A. Achour, and H. Skouri, “Hemodialysis duration, Human platelet antigen HPA-3 and IgA Isotype of anti-beta2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients,” Thrombosis Research, vol. 131, no. 5, pp. e202–e209, 2013. View at Google Scholar
  29. J. M. Morales, R. Marcén, A. Andrés et al., “Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease,” Kidney International, no. 111, pp. S94–S99, 2008. View at Google Scholar · View at Scopus
  30. D. S. Majka, K. Liu, R. M. Pope et al., “Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort,” Inflammation Research, vol. 62, no. 10, pp. 919–927, 2013. View at Google Scholar
  31. M. Blank, R. A. Asherson, R. Cervera, and Y. Shoenfeld, “Antiphospholipid syndrome infectious origin,” Journal of Clinical Immunology, vol. 24, no. 1, pp. 12–23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. A. McIntyre, D. R. Wagenknecht, and W. P. Faulk, “Antiphospholipid antibodies in heart transplant recipients,” Clinical Cardiology, vol. 18, no. 10, pp. 575–580, 1995. View at Google Scholar · View at Scopus
  33. A. Furmanczyk-Zawiska, O. Tronina, T. Baczkowska, A. Chmura, and M. Durlik, “The significance of antiphospholipid antibodies in liver recipients,” Transplantation Proceedings, vol. 45, no. 5, pp. 1983–1989, 2013. View at Google Scholar
  34. D. H. Van Thiel, M. George, J. Brems et al., “Antiphospholipid antibodies before and after liver transplantation,” American Journal of Gastroenterology, vol. 98, no. 2, pp. 460–465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. P. J. Phelan, P. O'Kelly, M. Tarazi et al., “Renal allograft loss in the first post-operative month: causes and consequences,” Clinical Transplantation, vol. 26, no. 4, pp. 544–549, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Morales, R. Marcen, D. del Castillo et al., “Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study,” Nephrology Dialysis Transplantation, vol. 27, supplement 4, pp. iv39–iv46, 2012. View at Google Scholar
  37. L. Ghisdal, N. Broeders, K. M. Wissing et al., “Thrombophilic factors in Stage v chronic kidney disease patients are largely corrected by renal transplantation,” Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2700–2705, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. J. Rowley, I. R. Mackay, and I. F. McKenzie, “Antibody production in immunosuppressed recipients of renal allografts,” The Lancet, vol. 2, no. 7623, pp. 708–710, 1969. View at Google Scholar · View at Scopus
  39. S. Heidt, D. L. Roelen, C. Eijsink et al., “Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help,” Clinical and Experimental Immunology, vol. 159, no. 2, pp. 199–207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Morell, F. Skvaril, G. Noseda, and S. Barandun, “Metabolic properties of human IgA subclasses,” Clinical and Experimental Immunology, vol. 13, no. 4, pp. 521–528, 1973. View at Google Scholar · View at Scopus
  41. D. Keeling, I. Mackie, G. W. Moore, I. A. Greer, and M. Greaves, “Guidelines on the investigation and management of antiphospholipid syndrome,” British Journal of Haematology, vol. 157, no. 1, pp. 47–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. R. H. W. M. Derksen and P. G. De Groot, “Towards evidence-based treatment of thrombotic antiphospholipid syndrome,” Lupus, vol. 19, no. 4, pp. 470–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Broder and C. Putterman, “Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus,” The Journal of Rheumatology, vol. 40, no. 1, pp. 30–33, 2013. View at Google Scholar
  44. A. Tripodi, P. G. de Groot, and V. Pengo, “Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment,” Journal of Internal Medicine, vol. 270, no. 2, pp. 110–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. G. Fonseca and D. P. D'Cruz, “Controversies in the antiphospholipid syndrome: can we ever stop warfarin?” Journal of Autoimmune Diseases, vol. 5, article 6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Pengo, “APS—controversies in diagnosis and management, critical overview of current guidelines,” Thrombosis Research, vol. 127, no. 3, pp. S51–S52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Pengo, A. Ruffatti, C. Legnani et al., “Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A Multicenter Prospective Study,” Blood, vol. 118, no. 17, pp. 4714–4718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Ruffatti, T. Del Ross, M. Ciprian et al., “Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1083–1086, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Ruffatti, T. Del Ross, M. Ciprian et al., “Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study,” Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 397–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Tsuruta, N. Ishii, and T. Hashimoto, “Diagnosis and treatment of pemphigus,” Immunotherapy, vol. 4, no. 7, pp. 735–745, 2012. View at Google Scholar
  51. M. Meurer, “Immunosuppressive therapy for autoimmune bullous diseases,” Clinics in Dermatology, vol. 30, no. 1, pp. 78–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. D. B. Sanders and A. Evoli, “Immunosuppressive therapies in myasthenia gravis,” Autoimmunity, vol. 43, no. 5-6, pp. 428–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Cartin-Ceba, T. Peikert, A. Ashrani et al., “Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage,” Arthritis Care & Research (Hoboken), vol. 66, no. 2, pp. 301–310, 2014. View at Google Scholar
  54. D. Roccatello, S. Sciascia, D. Rossi et al., “Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy,” Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 3987–3992, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Rubenstein, D. G. Arkfeld, S. Metyas, S. Shinada, S. Ehresmann, and H. A. Liebman, “Rituximab treatment for resistant antiphospholipid syndrome,” Journal of Rheumatology, vol. 33, no. 2, pp. 355–357, 2006. View at Google Scholar · View at Scopus
  56. H. Berman, I. Rodriguez-Pinto, R. Cervera et al., “Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab,” Autoimmunity Reviews, vol. 12, no. 11, pp. 1085–1090, 2013. View at Google Scholar
  57. D. Kumar and R. A. S. Roubey, “Use of rituximab in the antiphospholipid syndrome,” Current Rheumatology Reports, vol. 12, no. 1, pp. 40–44, 2010. View at Publisher · View at Google Scholar · View at Scopus